ArticleChest2026
Imaging-Based Pulmonary Hypertension Phenotypes in Connective Tissue Disease-Related Interstitial Lung Disease.
Article in Chest, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundPatients with connective tissue disease-related interstitial lung disease (CTD-ILD) may demonstrate pulmonary hypertension (PH) through pulmonary parenchymal destruction and chronic hypoxia or via endovascular changes driven by the underlying autoimmunity. Distinguishing which process-parenchymal or vascular-is the primary cause has important therapeutic and prognostic implications. RESEARCH QUESTION: Can chest imaging be used to classify patients with CTD-ILD and PH systematically as having a parenchymal or vascular PH phenotype? STUDY DESIGN AND
methodsChest CT imaging was used to classify 275 adult patients with CTD-ILD and PH in the Johns Hopkins ILD and PH registries as having a parenchymal or vascular PH phenotype. CT imaging-based PH phenotypes were determined using a validated ILD severity staging tool that involves visual inspection of the percentage of lung affected by CTD-ILD. The primary outcome was time to clinical worsening (defined as a composite of physiologic worsening, hospital admission for a pulmonary or cardiac diagnosis, lung transplantation, or death), which was compared between the 2 phenotypes. Secondary outcomes included comparisons of baseline cardiopulmonary testing results, time to physiologic worsening, time to hospital admission, and time to lung transplantation or death. Clinical outcomes also were compared between the CT imaging-based PH phenotypes and the conventional World Symposium on Pulmonary Hypertension (WSPH) group classifications.
resultsPatients with CTD-ILD and the parenchymal PH phenotype were 1.76 times more likely to experience clinical worsening than those with the vascular phenotype. They were also more likely to experience physiologic worsening, hospitalization, and lung transplantation or death. CT imaging-based PH phenotypes were associated more closely with clinical outcomes than the WSPH group classifications.
interpretationOur research shows that patients with CTD-ILD and the parenchymal PH phenotype have worse clinical outcomes than those with the vascular PH phenotype. CT imaging-based PH phenotypes may characterize patients' risk of clinical worsening more reliably than the WSPH groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.